Event Details Investor Update Call – ISTH July 08, 2019 8:00 AM EDT Supporting Materials Phase 2/3 Trial of Subcutaneous Engineered FVIIa Marzeptacog Alfa (Activated) in Hemophilia A or B with Inhibitors: Efficacy, Safety and Pharmacokinetics 394.8 KB Quality of Life of Hemophilia Patients with Inhibitors – Opportunities for Improvement 709 KB Phase 2 Trial of Subcutaneous Engineered FIX Dalcinonacog alfa: Pharmacokinetics and Safety 422.7 KB A Comprehensive In Silico And In Vitro Immunogenicity Risk Assessment of Dalcinonacog Alfa Shows No Increased Risk Compared With Wild-type FIX 1.8 MB Shareholder Tools Print Page RSS Feeds E-mail Alerts
Phase 2/3 Trial of Subcutaneous Engineered FVIIa Marzeptacog Alfa (Activated) in Hemophilia A or B with Inhibitors: Efficacy, Safety and Pharmacokinetics 394.8 KB
A Comprehensive In Silico And In Vitro Immunogenicity Risk Assessment of Dalcinonacog Alfa Shows No Increased Risk Compared With Wild-type FIX 1.8 MB
Investor Update Call – ISTH
